ZSWIM5 Inhibitors
ZSWIM5 inhibitors encompass a range of chemical compounds that interfere with various cellular pathways and processes, ultimately leading to the reduced functional activity of ZSWIM5. The selective cyclin-dependent kinase inhibitors PalZSWIM5 inhibitors encompass a range of chemical compounds that interfere with various cellular pathways and processes, ultimately leading to the reduced functional activity of ZSWIM5. The selective cyclin-dependent kinase inhibitors PD 0332991 and Rapamycin are key examples, with the former halting cell cycle progression and the latter suppressing mTOR signaling, both of which are crucial for the cellular functions regulated by ZSWIM5. Histone deacetylase inhibitors such as Trichostatin A may indirectly diminish ZSWIM5 activity by altering gene expression patterns. Similarly, LY 294002, a PI3K inhibitor, and SB 203580, a p38 MAPK inhibitor, disrupt signaling pathways that ZSWIM5 could regulate or interact with, thereby reducing its activity. Inhibition of the JNK pathway by SP600125 could also diminish the functional activity of ZSWIM5 in apoptosis or inflammation.
Continuing with the theme of pathway interference, MG-132 and Bortezomib disrupt proteasomal degradation, potentially leading to the accumulation of proteins that negatively regulate ZSWIM5's function. The DNA methyltransferase inhibitor 5-Azacytidine could affect ZSWIM5 by changing the expression of its regulatory proteins. PD 98059 and U0126, both MEK inhibitors, are likely to inhibit ZSWIM5 by impeding the ERK/MAPK signaling pathway, which may be integral to the functional activity of ZSWIM5. Lastly, W-7, as a calmodulin antagonist, may inhibit ZSWIM5 by disrupting calmodulin-mediated signaling processes. Collectively, these inhibitors attenuate ZSWIM5 activity through a multifaceted approach, targeting the intricate web of signaling pathways that regulate or interact with ZSWIM5.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
PD 0332991 is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. ZSWIM5 function is potentially influenced by cell cycle progression, and inhibition of CDK4/6 by Palbociclib could diminish ZSWIM5 activity by halting the cell cycle in the G1 phase, thereby affecting processes ZSWIM5 regulates during the cell cycle. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Because ZSWIM5 is implicated in processes that are regulated by mTOR signaling, such as protein synthesis and autophagy, rapamycin could inhibit ZSWIM5 by suppressing mTOR pathways, leading to reduced ZSWIM5-mediated protein interactions. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. Inhibiting histone deacetylase can alter chromatin structure and transcriptional regulation. As ZSWIM5 may be involved in gene expression regulation, Trichostatin A could indirectly diminish ZSWIM5 activity by changing the transcriptional landscape of proteins that interact with ZSWIM5. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a PI3K inhibitor. Considering that ZSWIM5 might interact with PI3K/Akt pathway components, inhibition of PI3K by LY 294002 would lead to decreased Akt phosphorylation and subsequent diminution of ZSWIM5 activity associated with this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. If ZSWIM5's activity is modulated by stress response pathways, such as those involving p38 MAPK, then SB 203580 would decrease ZSWIM5 activity by inhibiting these stress response pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. ZSWIM5 may be implicated in JNK pathway-mediated apoptosis or inflammation processes. Thus, inhibiting JNK with SP600125 would likely reduce ZSWIM5's involvement in these cellular responses. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor. ZSWIM5 might be regulated through proteasomal degradation. By preventing proteolysis with MG-132, the decrease in proteasome activity could lead to the accumulation of proteins that negatively regulate ZSWIM5's function. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor. Methylation status can impact gene expression profiles; hence, 5-Azacytidine could inhibit ZSWIM5 activity by altering the methylation and expression of genes coding for proteins that interact with or regulate ZSWIM5. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is another proteasome inhibitor that could affect the turnover of regulatory proteins involved in ZSWIM5's pathway, leading to a buildup of proteins that inhibit ZSWIM5 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is an MEK inhibitor that could diminish ZSWIM5 activity by impeding the ERK/MAPK signaling pathway, which may be involved in processes regulated by ZSWIM5. | ||||||